title: [Aggressive T cytotoxic CD8+ epidermotropic cutaneous lymphoma: a case in a patient with Steinert's myotonic dystrophy].
abstract: BACKGROUND
  Primary cutaneous "aggressive" CD8-positive epidermotropic cytotoxic T-cell lymphoma is a rare subset of cutaneous cytotoxic T/NK lymphomas that clearly differs from mycosis fungoides, whether CD4+ or CD8+, by the presence of rapidly evolving tumoral cutaneous lesions, foci of keratinocytes necrosis, a cytotoxic T phenotype and a poor prognosis.
  
  
  METHODS
  A 33-year-old man with Steinert's myotonic dystrophy was referred for evaluation of rapidly worsening cutaneous tumors along with marked deterioration of general status. Clinical, histological and immunohistological data led to the diagnosis of primary cutaneous CD8+ epidermotropic cytotoxic T-cell lymphoma. CHOP chemotherapy was effective despite cardiac toxicity in the setting of Steinert's dystrophy, but the patient relapsed and died of pulmonary sepsis after chemotherapy was resumed.
  
  
  CONCLUSIONS
  The treatment of primary cutaneous epidermotropic CD8+ cytotoxic T-cell lymphoma is not codified. CHOP chemotherapy is usually the first-line therapy but relapses are frequent with median survival of no more than 34 months. In our patient, an additional difficulty was the cardiac toxicity of cytostatic drugs linked to the myopathy which prevented the use of high dosages, requiring a change of therapeutic regimen.
authors.affiliation: Service de Dermatologie, Laboratoire d'Anatomie Pathologique, CHRU Montpellier.
authors.forename: A
authors.initials: A
authors.lastname: Du-Thanh
authors.forename: L
authors.initials: L
authors.lastname: Durand
authors.forename: V
authors.initials: V
authors.lastname: Costes
authors.forename: B
authors.initials: B
authors.lastname: Guillot
authors.forename: O
authors.initials: O
authors.lastname: Dereure
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009223:Myotonic Dystrophy / Q000150:complications*; D011241:Prednisone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone